NCT04851574View on ClinicalTrials.gov

PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

January 20, 2020

Study Completion Date

January 29, 2020

Conditions
General Anesthetic Drug Adverse Reaction
Interventions
DRUG

Sugammadex Injection

Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.

Trial Locations (1)

60-572

Alicja Bartkowska-Sniatkowska, Poznan

All Listed Sponsors
lead

Poznan University of Medical Sciences

OTHER

NCT04851574 - PKPD of Rocuronium and Sugammadex Profile in Pediatric Patients | Biotech Hunter | Biotech Hunter